JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

doi:10.1158/2159-8290.CD-14-0736

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Cancer discovery - 1 Mar 2015

Kleppe Maria, Kwak Minsuk, Koppikar Priya, Riester Markus, Keller Matthew, Bastian Lennart, Hricik Todd, Bhagwat Neha, McKenney Anna Sophia, Papalexi Efthymia, Abdel-Wahab Omar, Rampal Raajit, Marubayashi Sachie, Chen Jonathan J, Romanet Vincent, Fridman Jordan S, Bromberg Jacqueline, Teruya-Feldstein Julie, Murakami Masato, Radimerski Thomas, Michor Franziska, Fan Rong, Levine Ross L

Abstract excerpt

UNLABELLED: The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) has led to the clinical development of JAK kinase inhibitors, including ruxolitinib. Ruxolitinib reduces splenomegaly and systemic symptoms in myelofibrosis and improves overall survival; however, the mechanism by which JAK inhibitors achieve efficacy has not been delineated. Patients with MPN present with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Inflammation Mediators

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 1

Share to Janus Kinases

Share to Leukocyte Common Antigens

Share to Myeloid Cells

Share to Myeloproliferative Disorders

Share to Primary Myelofibrosis

Share to STAT Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 25572172
DOI: 10.1158/2159-8290.CD-14-0736
PMCID: PMC4355105

Genes

JAK2
MPL
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.PMID 25572172Read ↗

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Immunological Consequences of JAK Inhibition: Friend or Foe?Semantic proximity Read ↗

Biology and therapeutic targeting of molecular mechanisms in MPNs.Semantic proximity Read ↗

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Semantic proximity Read ↗

Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.Semantic proximity Read ↗

Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.Semantic proximity Read ↗

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.Semantic proximity Read ↗

JAK2 in Myeloproliferative Neoplasms: Still a ProtagonistSemantic proximity Read ↗

Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics.Semantic proximity Read ↗

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.Semantic proximity Read ↗

Pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.